Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$10M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$181M |
Are Filana Therapeutics Insiders Buying or Selling?
Filana Therapeutics (FLNA) has had 2 insider transactions in the past 90 days, all buys — insider buying is generally read as a bullish signal. The most recent was Richard Barry, who bought 100,000 shares at $0.92 on September 30, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the FLNA AI Score. For government officials trading this stock, see FLNA congressional trading.
Who’s Trading Filana Therapeutics Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Richard Barry | Bought $280,000 | 2 | Sep 30, 2026 |
Recent Filana Therapeutics Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Richard Barry | Sep 30, 2026 | Buy | 100,000 | $0.92 | $92,000 |
| Richard Barry | Sep 29, 2026 | Buy | 206,813 | $0.9 | $190,000 |
Frequently Asked Questions: Filana Therapeutics Insider Trading
In the past 90 days, Filana Therapeutics insiders have made 2 buys and 0 sells. The net buying may indicate insider confidence in the company’s outlook.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Barry Richard has bought the most FLNA stock in the last 2 years, with a total value of $280,000.
According to our estimates, the total value of insider transactions for Filana Therapeutics in the last 2 years is positive, amounting to $280,000. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
